Clinical Observation Of Levosimendan Improving Cardiac Function In Postoperative Patients Severe Cardiac Valve Disease

ObjectiveLevosimendan in severe heart valve heart valve replacement surgerytreatment, the patient for levosimendan security, is widely used in postoperativetreatment of severe cardiac valve disease clinical trials provide scientific andreliable basis.MethodsWe put severe after the replacement of heart valve disease patients into twogroups, one group of levosimendan, a set of no use. Each group has30people,the former as the experimental group, the latter to the control group.Two groupsof patients after surgery adopts the traditional strong heart, diuresis medicine,ACEI, nitrates, angiotensin II receptor antagonist drugs （ARB）, beta blockersand other drugs.Examination in patients with severe valvular surgery after thestable blood volume, micro pump pumping levosimendan injections for24hours(0.2μg·kg^-1·min^-1).We compared two groups of postoperative urinary volume,type B urine sodium peptide decreased, LVEF and SV of rise and decline ofPCWP, central venous pressure, length of hospital stay, postoperative dyspneaand systemic symptoms, comprehensive evaluation of drug efficacy and safety.ResultsWe found that the urine after surgery, type B urine sodium peptidedecreased ejection fraction,LVEF, left heart and stroke volume SV increase,pulmonary artery wedge pressure drop, central venous pressure, postoperativelength of hospital stay these projects, the treatment group is better than thecontrol group.The significant improvement in experimental group patients withdyspnea （94.1%）, control group was67.8%.Examination in patients with systemic clinical symptoms improved97.1%, control group was71.0%.Twogroups of patients had no serious adverse events.Group the incidence of adversereactions was8.8%, control group is41.9%（P<0.05）.Common adverse reactionswere headache, hypotension, and hypokalemia.ConclusionLevosimendan injection for severe cardiac valve disease curative effectafter operation.We found that the urine after surgery, type B urine sodiumpeptide decreased ejection fraction,LVEF, left heart and stroke volume SVincrease, pulmonary artery wedge pressure drop, central venous pressure,postoperative length of hospital stay these projects, the treatment group is betterthan the control group.Levosimendan can obviously improve the patient’sbreathing difficulties and other symptoms and signs, improve the quality of lifeof patients.Levosimendan injection is safe and effective and can be used forsevere cardiac valve disease, and is expected to replace the other traditionalpositive inotropic drug types.